18F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: Prospective comparison with standard imaging

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 1, 2011, Pages 14-22

  McCarthy, Michael ^a,b   Siew, Teck ^a,b   Campbell, Andrew ^a   Lenzo, Nat ^b   Spry, Nigel ^b,c   Vivian, Justin ^a   Morandeau, Laurence ^b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Bone scan; Castration resistant prostate cancer; CT; FCH; Fluoromethylcholine; PET

Indexed keywords

CHOLINE FENOFIBRATE; FLUORODEOXYGLUCOSE F 18; FLUOROMETHYLCHOLINE; UNCLASSIFIED DRUG; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROSTATE CARCINOMA; SENSITIVITY AND SPECIFICITY; SOFT TISSUE DISEASE; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; ORCHIECTOMY; PROSTATE TUMOR; RADIOGRAPHY; SCINTISCANNING; WHOLE BODY IMAGING;

AGED; AGED, 80 AND OVER; CHOLINE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 79551528020     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1579-x     Document Type: Article

References (23)

1. J Kotzerke JE Gschwend B Neumaier 2002 PET for prostate cancer imaging: still a quandary or the ultimate solution? J Nucl Med 43 200 202 11850484
2. CK Hoh MA Seltzer J Franklin JB deKernion ME Phelps A Belldegrun 1998 Positron emission tomography in urological oncology J Urol 159 347 356 1:CAS:528:DyaK1cXmsFOhsr8%3D 10.1016/S0022-5347(01)63916-8 9649238 (Pubitemid 28049232)
3. D Mathews OK Oz 2002 Positron emission tomography in prostate and renal cell carcinoma Curr Opin Urol 12 381 385 10.1097/00042307-200209000-00003 12172424
4. PJ Effert R Bares S Handt JM Wolff U Büll G Jakse 1996 Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose J Urol 155 994 998 1:STN:280: DyaK287msVKnug%3D%3D 10.1016/S0022-5347(01)66366-3 8583625 (Pubitemid 26052696)
5. PD Shreve HB Grossman MD Gross RL Wahl 1996 Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose Radiology 199 751 756 1:STN:280:DyaK283itVGgug%3D%3D 8638000
6. H Schöder SM Larson 2004 Positron emission tomography for prostate, bladder, and renal cancer Semin Nucl Med 34 274 292 10.1053/j.semnuclmed.2004. 06.004 15493005 (Pubitemid 39365998)
7. T Kato E Tsukamoto Y Kuge T Takei T Shiga N Shinohara, et al. 2002 Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer Eur J Nucl Med Mol Imaging 29 1492 1495 1:CAS:528:DC%2BD38XotV2it74%3D 10.1007/s00259-002-0885-3 12397469 (Pubitemid 35232052)
8. DT Schmid H John R Zweifel T Cservenyak G Westera GW Goerres, et al. 2005 Fluorocholine PET/CT in patients with prostate cancer: initial experience Radiology 235 623 628 10.1148/radiol.2352040494 15858102 (Pubitemid 40571106)
9. IJ de Jong J Pruim PH Elsinga W Vaalburg HJA Mensink 2003 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer Eur Urol 44 32 38 10.1016/S0302-2838(03)00207-0 12814672 discussion 38-39 (Pubitemid 36741372)
10. E Fricke S Machtens M Hofmann J van den Hoff S Bergh T Brunkhorst, et al. 2003 Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients Eur J Nucl Med Mol Imaging 30 607 611 1:CAS:528: DC%2BD3sXislyqtrg%3D 10.1007/s00259-002-1104-y 12589476
11. K Bouchelouche P Oehr 2008 Recent developments in urologic oncology: positron emission tomography molecular imaging Curr Opin Oncol 20 321 326 1:CAS:528:DC%2BD1cXktlSksbk%3D 10.1097/CCO.0b013e3282f8b02b 18391633 (Pubitemid 351507554)
12. T Hara 2001 18F-Fluorocholine: a new oncologic PET tracer J Nucl Med 42 1815 1817 1:STN:280:DC%2BD38%2FgtlOgsA%3D%3D 11752078
13. TR DeGrado RE Coleman S Wang SW Baldwin MD Orr CN Robertson, et al. 2001 Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer Cancer Res 61 110 117 1:CAS:528:DC%2BD3MXlsl2lsA%3D%3D 11196147
14. T Hara N Kosaka H Kishi 2002 Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging J Nucl Med 43 187 199 1:CAS:528:DC%2BD38XjvFWjtrs%3D 11850483
15. TR DeGrado RE Reiman DT Price S Wang RE Coleman 2002 Pharmacokinetics and radiation dosimetry of 18F-fluorocholine J Nucl Med 43 92 96 1:CAS:528:DC%2BD38XksVynu7c%3D 11801711
16. M Beheshti R Vali P Waldenberger F Fitz M Nader W Loidl, et al. 2008 Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study Eur J Nucl Med Mol Imaging 35 1766 1774 10.1007/s00259-008-0788-z 18465129
17. M Cimitan E Borsatti R Tatta A Drigo L Rampin D Rubello 2005 Uptake of 18F-fluorocholine (FCH) by bone metastases of prostate carcinoma: what's the best timing for FCH PET acquisition J Nucl Med 46 Suppl 2 432
18. O Schillaci F Calabria M Tavolozza C Cicciò M Carlani CR Caracciolo, et al. 2010 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer Nucl Med Commun 31 39 45 1:CAS:528:DC%2BC3cXpsF2gsA%3D%3D 10.1097/MNM. 0b013e328330adc5 19972635
19. M Beheshti L Imamovic G Broinger R Vali P Waldenberger F Stoiber, et al. 2010 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients Radiology 254 925 933 10.1148/radiol.09090413 20177103
20. R Schiavina V Scattoni P Castellucci M Picchio B Corti A Briganti, et al. 2008 11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms Eur Urol 54 392 401 10.1016/j.eururo.2008.04.030 18456393
21. Poulsen MH, Bouchelouche K, Gerke O, Petersen H, Svolgaard B, Marcussen N, et al. [(18)F]-fluorocholine positron-emission/computed tomography for lymph node staging of patients with prostate cancer: preliminary results of a prospective study. BJU Int 2010;Epub ahead of print.
22. M Beheshti R Vali P Waldenberger F Fitz M Nader J Hammer, et al. 2010 The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT Mol Imaging Biol 12 98 107 10.1007/s11307-009-0239-7 19588206
23. DT Price RE Coleman RP Liao CN Robertson TJ Polascik TR DeGrado 2002 Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer J Urol 168 273 280 10.1016/S0022-5347(05)64906-3 12050555